BACKGROUND AND OBJECTIVES: Iron accumulation is an inevitable consequence of
chronic blood transfusions and results in serious complications in the absence of chelation …

Tens of thousands of transfusion-dependent (eg, thalassemia) patients worldwide suffer
from chronic iron overload and its potentially fatal complications. The oral iron chelator …

Nontransfusion-dependent thalassemia (NTDT) patients may develop iron overload and its
associated complications despite receiving only occasional or no transfusions. The present …

Deferasirox (ICL670) is a once-daily oral iron chelator developed for the treatment of chronic
iron overload from blood transfusions. A comparative phase 3 trial was conducted to …

For nearly 30 years, patients with transfusional iron overload have depended on nightly
deferoxamine infusions for iron chelation. Despite dramatic gains in life expectancy in the …

Deferasirox is an oral iron chelator, with a long half-life, that can be given once daily,
because it provides a 24-hour chelation. Several phase II trials and a pivotal phase III trial …

Patients with non-transfusion-dependent thalassemia (NTDT) often develop iron overload
that requires chelation to levels below the threshold associated with complications. This can …

En Summary Abstract Deferasirox (Exjade®) is an oral, once-daily iron chelator widely
approved for the treatment of transfusional chronic iron overload. In the EU, deferasirox is …

Whereas RBC transfusion therapy is lifesaving in thalassemia, obligatory iron loading
accompanies such treatment and chelation therapy to remove and detoxify iron resulting …

Although blood transfusions are important for patients with anemia, chronic transfusions
inevitably lead to iron overload as humans cannot actively remove excess iron. The …